Business
Novo Nordisk to Cut 9,000 Jobs Amid Rising Obesity Drug Competition
Novo Nordisk announced on Wednesday it will cut more than 11 percent of its global workforce, or 9,000 jobs, as the Danish pharmaceutical company faces intensifying competition in the obesity drug market and lowered profit expectations for the year.
The move comes as US rival Eli Lilly gains market share with its own weight-loss treatments, putting pressure on Novo’s flagship products, Ozempic and Wegovy. Around 5,000 of the job losses will be in Denmark, where the company is headquartered. Novo said the restructuring would generate annual savings of DKK8 billion (€1.1 billion) by 2026, though it will incur restructuring charges of a similar amount upfront.
The company also cut its operating profit forecast for 2025 for the third time this year, now projecting growth of 4–10 percent, compared with its previous estimate of 10–16 percent. In a statement, Novo described the restructuring as a strategic shift aimed at “meeting rising global demand while also competing in a more dynamic and consumer-driven obesity market.”
CEO Mike Doustdar acknowledged the growing pressure from rivals, noting that the weight-loss market has become “more competitive.” Eli Lilly has surged ahead with its blockbuster drug Mounjaro, while cheaper alternatives and copycat versions of Novo’s treatments have added further challenges.
The announcement follows months of turbulence for the drugmaker. In July, Doustdar took over as CEO after Lars Fruergaard Jorgensen stepped down, partly due to disappointing trial results for Novo’s experimental obesity drug CagriSema. The setback dented investor confidence and wiped billions from the company’s market value. A global hiring freeze imposed in August further signaled that cost-cutting was a top priority.
“Disappointing drug trials have cast a dark cloud on the business, wiping billions of dollars off its market valuation and costing CEO Lars Fruergaard Jorgensen his job,” said Russ Mould, investment director at AJ Bell. He added that the job losses were “a classic response to a strategic setback, aiming to refocus the company on what it does best while also trimming the fat to help reduce costs.”
Despite the announcement, Novo Nordisk’s shares rose more than 2 percent in Copenhagen trading on Wednesday morning, suggesting investors were encouraged by the restructuring plan.
The layoffs and revised forecasts mark one of the company’s most significant shifts in years, as it seeks to defend its dominant position in the booming but increasingly contested obesity drug market.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
